Celcuity, Inc. $CELC Shares Bought by Swiss National Bank

Swiss National Bank lifted its stake in shares of Celcuity, Inc. (NASDAQ:CELC) by 64.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 41,200 shares of the company’s stock after purchasing an additional 16,100 shares during the quarter. Swiss National Bank’s holdings in Celcuity were worth $4,703,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Avoro Capital Advisors LLC acquired a new position in Celcuity during the 4th quarter valued at about $310,302,000. NEA Management Company LLC lifted its stake in shares of Celcuity by 64.9% in the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after acquiring an additional 1,391,300 shares during the period. State Street Corp boosted its holdings in shares of Celcuity by 126.6% in the fourth quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after acquiring an additional 914,887 shares in the last quarter. UBS Group AG boosted its holdings in shares of Celcuity by 910.1% in the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after acquiring an additional 769,891 shares in the last quarter. Finally, Deerfield Management Company L.P. bought a new position in shares of Celcuity in the third quarter valued at approximately $36,236,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

Celcuity Stock Performance

Shares of CELC opened at $83.21 on Thursday. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. The firm’s 50 day moving average is $100.93 and its 200-day moving average is $109.92. Celcuity, Inc. has a 12-month low of $38.00 and a 12-month high of $151.02. The stock has a market capitalization of $4.06 billion, a P/E ratio of -21.34 and a beta of 0.16.

Celcuity (NASDAQ:CELC) last released its earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.10. Equities research analysts anticipate that Celcuity, Inc. will post -3.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on CELC shares. Craig Hallum reissued a “buy” rating and set a $178.00 target price on shares of Celcuity in a report on Wednesday, July 15th. Weiss Ratings raised Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. HC Wainwright lifted their price target on Celcuity from $145.00 to $155.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Citigroup reissued an “outperform” rating on shares of Celcuity in a research note on Wednesday, July 15th. Finally, Needham & Company LLC restated a “buy” rating and issued a $157.00 price objective on shares of Celcuity in a report on Friday, May 15th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $155.18.

Insider Buying and Selling at Celcuity

In related news, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at $949,509.60. The trade was a 57.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the sale, the director directly owned 65,000 shares in the company, valued at $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is currently owned by corporate insiders.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.